[Medicoeconomic data on rare disease drugs: a move towards more transparency?].
作者信息
Schwebig Annick, Duguet Christophe, Ferry Antoine, Bougé Claude, Fagon Jean-Yves, Bismuth Catherine, Ramon Jacques
机构信息
Actelion pharmaceuticals France SAS, 75001 Paris, France.
出版信息
Presse Med. 2012 May;41 Suppl 1:S57-64. doi: 10.1016/j.lpm.2012.02.024. Epub 2012 Apr 8.
PMID:22487716
Abstract
摘要
相似文献
1
[Medicoeconomic data on rare disease drugs: a move towards more transparency?].[罕见病药物的药物经济学数据：朝着更高透明度迈进？]
Presse Med. 2012 May;41 Suppl 1:S57-64. doi: 10.1016/j.lpm.2012.02.024. Epub 2012 Apr 8.
2
Small biotechs raring to cash in on the orphan disease market.小型生物技术公司渴望在罕见病市场获利。
Nat Med. 2012 Mar 6;18(3):330-1. doi: 10.1038/nm0312-330.
3
Drug patent plan gets mixed reviews.药品专利计划毁誉参半。
Nature. 2009 Feb 26;457(7233):1064. doi: 10.1038/4571064a.
4
Jumpstarting research into neglected diseases.启动对被忽视疾病的研究。
Cell. 2006 Nov 3;127(3):443-5. doi: 10.1016/j.cell.2006.10.022.
5
A new era of hope for the world's most neglected diseases.世界上最被忽视疾病的希望新时代。
PLoS Med. 2005 Sep;2(9):e323. doi: 10.1371/journal.pmed.0020323. Epub 2005 Sep 8.
6
A breakthrough in R&D for neglected diseases: new ways to get the drugs we need.被忽视疾病研发领域的一项突破：获取我们所需药物的新途径。
PLoS Med. 2005 Sep;2(9):e302. doi: 10.1371/journal.pmed.0020302. Epub 2005 Sep 8.
7
Orphan economics: the downside of supplyside pharmacology.罕见病药物经济学：供应方药理学的弊端
Ann Neurol. 2008 Sep;64(3):A13-6. doi: 10.1002/ana.21432.
8
[Conference 1. An economic observatory for orphan drugs: myth or reality?].[会议1. 罕见病药物的经济观测站：神话还是现实？]
Med Sci (Paris). 2014 Apr;30 Spe(1):21-3. doi: 10.1051/medsci/201430s105. Epub 2014 Apr 14.
9
Pharmaceutical expenditure and therapeutic value of new medicines in Spain.西班牙新药的药品支出与治疗价值
Pharmacoeconomics. 2003;21(16):1211-2. doi: 10.2165/00019053-200321160-00005.
10
[The challenges of medicoeconomic assessment, benefit for the patient].[药物经济学评估的挑战，对患者的益处]
Presse Med. 2012 May;41 Suppl 1:S29-31. doi: 10.1016/j.lpm.2012.02.031. Epub 2012 Apr 12.
Zotero 插件